COMydAL Program
We are excited to welcome you to participate in the 1st World Congress on Controversies in MDS and AML (COMydAL), which will be held virtually over the days of September 22-23, 2022, in parallel with the 2022 IACH Meeting.
This inaugural program will bring to the forefront the latest and most controversial date and information in the field of MDS and AML, providing a unique opportunity for world-class leaders in the field to debate vital issues – thank you for joining!
| DAY 1 – AML Thursday, September 22, 2022 Co-chairs: Amer Zeidan, USA and Andrew Wei, Australia |
|
| 13:15-13:30 | Welcome Address |
| 13:30-14:30 | Session 1 |
| Debate: Therapeutic decisions based on MRD in AML: Ready for prime time? | |
| 13:30-13:45 | Yes: Christopher Hourigan, USA |
| 13:45-14:00 | No: Christopher Gibson, USA |
| 14:00-14:15 | Case studies of MRD use for therapeutic decisions in AML: Andrew Wei, Australia |
| 14:15-14:30 | Panel discussion |
| 14:30-15:30 | Session 2 |
| Debate: Which FLT3 inhibitor to use in frontline therapy in FLT3 mutated AML? | |
| 14:30-14:45 | Midostaurin: Richard Stone, USA |
| 14:45-15:00 | Quizartinib: Harry Erba, USA |
| 15:00-15:15 | Case studies of FLT3 inhibitors in AML: Selina Luger, USA |
| 15:15-15:30 | Panel discussion |
| 15:30-16:30 | Session 3 |
| Debate: Intensive chemotherapy or Ven-based lower intensity regimens for older FIT AML patients? | |
| 15:30-15:45 | Intensive chemo: Jessica Altman, USA |
| 15:45-16:00 | Non-intensive chemo: Nicholas Short, USA |
| 16:00-16:15 | Case studies: Can we cease VEN-AZA in patients in long-term remission? Chong Chyn Chua, Australia |
| 16:15-16:30 | Panel discussion |
| 16:30-17:30 | Session 4 |
| Debate: Should we use maintenance therapy post allogeneic transplant in AML? | |
| 16:30-16:45 | Yes: Lohith Gowda, USA |
| 16:45-17:00 | No: Catherine Lai, USA |
| 17:00-17:15 | Case studies of how I use maintenance therapies post alloBMT in AML: TBA |
| 17:15-17:30 | Panel discussion |
| 17:30-18:30 | Session 5 |
| 17:30-17:45 | Will immune checkpoint inhibition find a way in AML and MDS? Naval Daver, USA |
| 17:45-18:00 | Will CAR therapies find a way in AML and MDS? Monica Guzman, USA |
| 18:00-18:15 | Case studies: How I use immune therapies in AML and MDS: Ivana Gojo, USA |
| 18:15-18:30 | Panel discussion |
| 18:30-19:30 | Session 6 |
| Debate: In 10 years we will cure most AML patients without transplant | |
| 18:30-18:45 | Yes: Tapan Kadia, USA |
| 18:45-19:00 | No: Gail Roboz, USA |
| 19:00-19:15 | Case studies: How I decide on recommending alloBMT in AML: Michael Heuser, Germany |
| 19:15-19:30 | Panel discussion |
| DAY 2 – MDS Friday, September 23, 2022 Co-chairs: Amer Zeidan, USA and Valeria Santini, Italy |
|
| 11:00-12:00 | Session 7 |
| Debate: Are we ready for clinical trials with triplets in HR-MDS? | |
| 11:00-11:15 | Yes: Uwe Platzbecker, Germany |
| 11:15-11:30 | No: TBA |
| 11:30-11:45 | Case studies: When do I use combination therapy in HR-MDS in my clinic? Amy DeZern, USA |
| 11:45-12:00 | Panel discussion |
| 12:00-13:00 | Session 8 |
| Debate: Overall survival should be the basis of any approval in HR-MDS | |
| 12:00-12:15 | Yes: Uma Borate, USA |
| 12:15-12:30 | No: Amy DeZern, USA |
| 12:30-12:45 | Case studies: How do I use “less than CR” responses in HR-MDS in my clinic to direct therapy: Anne Sophie Kubasch, Germany |
| 12:45-13:00 | Panel discussion |
| 13:00-14:00 | Session 9 |
| Debate: Can observation be a good choice in some cases of higher risk MDS? | |
| 13:00-13:15 | Yes: Valeria Santini, Italy |
| 13:15-13:30 | No: Pierre Fenaux, France |
| 13:30-13:45 | Case studies: How do I use observation in management of lower and higher risk MDS? Elizabeth Griffiths, USA |
| 13:45-14:00 | Panel discussion |
| Program pause | |
| 16:00-17:00 | Session 10 |
| Debate: Should we give HMA before alloBMT for HR-MDS with 5-9% blasts? | |
| 16:00-16:15 | Yes: Maximilian Stahl, USA |
| 16:15-16:30 | No: Emanuele Angelucci, Italy |
| 16:30-16:45 | Case studies: bridging therapy choices before alloBMT in HR-MDS: Hetty Carraway, USA |
| 16:45-17:00 | Panel discussion |
| 17:00-18:00 | Session 11 |
| Debate: The primary risk stratification tool in MDS should become IPSS-M | |
| 17:00-17:15 | Yes: Rafael Bejar, USA |
| 17:15-17:30 | No: Aziz Nazha, USA |
| 17:30-17:45 | Case studies: How do I use the different MDS stratification tools in my clinic: Aditi Shastri, USA |
| 17:45-18:00 | Panel discussion |
| 18:00-19:00 | Session 12 |
| Debate: Why do we keep having failed phase 3 trials in HR-MDS? | |
| 18:00-18:15 | Bad drugs: Steven Gore, USA |
| 18:15-18:30 | Bad trial designs: Mikkael Sekeres, USA |
| 18:30-18:45 | Overview of exciting drugs in lower and higher risk MDS: Amer Zeidan, USA |
| 18:45-19:00 | Panel discussion |
| 19:00-19:15 | Closing Remarks |